Mesenchymal STRO-1/STRO-3+ precursor cells for the treatment of chronic heart failure with reduced ejection fraction
Andrew Sundin1, Simona I Ionescu1, Wayne Balkan1,2
1Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Insights
Bone marrow-derived mesenchymal stem cells show promise in repairing cardiac injury for heart failure patients. Clinical trials indicate safety and efficacy, paving the way for revolutionary heart failure treatments.
Area of Science:
- Cardiology
- Regenerative Medicine
- Cell-based Therapy
Background:
- Myocardial injury triggers inflammatory and fibrotic responses, worsening cardiac dysfunction.
- Current heart failure treatments optimize cardiac function but do not repair underlying injury.
- Cell-based therapy offers potential for reversing cardiac damage.
Purpose of the Study:
- To examine phase II and III studies of bone marrow-derived mesenchymal STRO-1+ or STRO-1/STRO-3+ precursor cells.
- To assess the safety and efficacy of cell-based therapy in patients with heart failure with reduced ejection fraction.
- To determine optimal dosing and future directions for cell-based heart failure treatment.
Main Methods:
- Review of multiple clinical trials (Phase II and III) involving mesenchymal precursor cells.
- Evaluation of safety and efficacy data in patients with ischemic and non-ischemic heart failure with reduced ejection fraction.
- Analysis of optimal cell dosage and treatment protocols.
Main Results:
- Mesenchymal precursor cell therapy demonstrated safety and efficacy in clinical trials.
- Evidence suggests potential for repairing cardiac injury and improving cardiac function.
- Optimal dosing strategies are being refined through ongoing research.
Conclusions:
- Cell-based therapy using bone marrow-derived mesenchymal precursor cells is a promising approach for heart failure.
- Further research and clinical trials are needed to optimize treatment and revolutionize heart failure management.
- This therapy targets the underlying cardiac injury, offering a novel therapeutic strategy.
Abstract:
The heart is susceptible to proinflammatory and profibrotic responses after myocardial injury, leading to further worsening of cardiac dysfunction. Important developments in the management of heart failure with reduced ejection fraction have reduced morbidity and mortality; however, these therapies focus on optimizing cardiac function through hemodynamic and neurohormonal pathways and not by repairing the underlying cardiac injury. The potential of cell-based therapy to reverse cardiac injury has received substantial attention. Herein are examined the phase II and III studies of bone marrow-derived mesenchymal STRO-1+ or STRO-1/STRO-3+ precursor cells in patients with ischemic and nonischemic heart failure with reduced ejection fraction, addressing the safety and efficacy of cell-based therapy throughout multiple clinical trials, the optimal dose and the steps toward revolutionizing the treatment of heart failure.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:19Mesenchymal Stem Cells